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cine for use in immunocompetent adults aged 60 years and older, HZ continues to 
impact the American public and a better understanding of its current incidence 
is needed. METHODS: This was a retrospective analysis using the Truven Health 
MarketScan® databases from 2011. Cases were identified by a diagnosis code for 
HZ (ICD-9-CM: 053.xx) and must have been enrolled as of January 1, 2011, lacked 
a claim for shingles vaccination or HZ in the 90 days prior to this date, and been 
deemed immunocompetent according to the study criteria. Annual incidence rates 
were calculated for the entire population observed in the database as well as by 
gender and age group; standardized incidence rates were also produced using the 
2010 U.S. Census data. RESULTS: The annual incidence rate of HZ across all ages 
of the study population in 2011 was 4.47 per 1000 person-years (95% CI: 4.45, 4.50). 
This rate increased monotonically with age, ranging from 0.86 (95% CI: 0.84, 0.88) 
for those aged ≤ 19 to 12.78 (95% CI: 12.49, 13.07) for immunocompetent enrollees 
aged 80 and older. The incidence rate was 8.46 (95% CI: 8.39, 8.52) among adults 50 
years and older and 10.46 (95% CI: 10.35, 10.56) among those aged 60 years and older. 
The annual incidence rate of HZ was higher in women than men ((5.25, 95% CI: 5.21, 
5.29 and 3.66, 95% CI: 3.62, 3.69), respectively) and was seen across all age groups. 
When standardized using 2010 U.S. Census data, the annual incidence rate was 4.63 
per 1000 person-years (95% CI: 4.61, 4.66). CONCLUSIONS: Herpes zoster remains 
common among immunocompetent adults with incidence rates of HZ observed to 
increase with age and be higher in women than men.
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OBJECTIVES: Infective endocarditis (IE) is one of the most common hospital-
acquired infections. This study used Medicare claims data to understand the cur-
rent hospital-acquired infective endocarditis (HAIE) burden and associated risk 
factors. METHODS: The analysis was conducted using 2011 and 2012 Centers for 
Medicare and Medicaid Services Part A fee-for-service claims. Patients with an IE 
ICD-9 diagnosis code in 2012 and at least 6-months of follow-up were included. HAIE 
was defined as IE with 1) onset ≥ 72 h after admission or 2) a significant invasive 
procedure performed during a hospitalization ≤ 8 weeks before the onset. To meas-
ure the impact of HAIE versus non-HAIE on medical costs, a generalized estimat-
ing equation approach with a gamma distribution and log link function was used. 
Logistic regression was used to assess patient demographics’ and comorbidities’ 
association with HAIE. RESULTS: 10,059 IE patients were identified, 27% of which 
had HAIE. The 6-month death rate of HAIE patients was higher than non-HAIE 
patients (43% vs. 32%, p< 0.0001). HAIE patients had more hospitalizations (7.1 vs. 
3.9, p< 0.0001) and longer lengths of stay (27.7 vs. 14.1 days, p < 0.0001) after their 
IE onset. After adjusting for demographics, pre-existing health status (measured 
by Charlson Comorbidity Index) and hospital-level factors, HAIE patients had sig-
nificantly higher 6-month medical costs than non-HAIE patients (mean = $97,226 
vs. $39,032, p< 0.0001).Patients with liver disease or hemiplegia were at the high-
est risk of HAIE, with odds ratios of 1.9 and 2.6, respectively, while adjusting for 
covariates. CONCLUSIONS: Medicare HAIE patients had higher healthcare costs, 
underscoring the need to further understand the risk factors for hospital versus 
community-acquired IE. Our study showed that patients with certain pre-existing 
comorbidities have a higher risk of HAIE. Using this information, healthcare pro-
viders may be able to better prevent HAIE and avoid its associated mortality risk 
and costs.
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OBJECTIVES: Determine the factors associated with loss to follow-up (LTFU) in 
people living with HIV on antiretroviral therapy (HAART) in Mexico. METHODS: 
A case-control study in people living with HIV on HAART was conducted using 
the national database of the System of management, logistic and monitoring of 
antiretroviral (SALVAR) of the National Center for the Prevention and Control of 
HIV and Aids (CENSIDA). Subjects included in the study had begun HAART with at 
least 18 years age, between January 2009 and December 2013. LTFU was defined as 
not attending the clinic for a period of 6 months or longer, while not yet classified 
as dead or transferred-out. Patients in HAART until the end of the study or dead 
during treatment were considered to be controls. The unmatched sample size was 
estimated with a 95%CIs and 1:2 ratio of cases-to-control. A simple random sam-
pling technique was used to select the sample cases and controls (330 cases and 
660 controls). A logistic regression analysis was run using Stata 11.1. RESULTS: In 
multivariable analysis the time between the diagnostic and linkage to care ≥ 50 days 
(OR 1.87; 95%CIs 1.29-2.73) was associated with LTFU (p< 0.05). Once-daily single 
tablet regimen (OR 0.33; 95%Cis 0.23-0.46), age of start of treatment ≥ 41 years old 
(OR 0.57; 95%CIs 0.39-0.83), 4th year since linkage to care (OR 0.11; 95%CIs 0.04-0.29) 
compared to first year, and last viral load < 50 RNA copies/mL (OR 0.24; 95%CIs 
0.17-0.33) had reduced odds of being LTFU. CONCLUSIONS: Number of pills per 
day had a significant impact on the risk to LTFU and an undetectable viral load had 
a positive feedback in the retention to treatment. The data reflects the importance 
of continuing research on co-formulated antiretroviral regimens.
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hospital-based outpatient wound centers. Patient, wound and encounter level char-
acteristics were examined. Treatment of interest was enzymatic debridement with 
clostridial collagenase ointment (CCO). RESULTS: A total of 9,203 patients, 20,358 
wounds, and 149,680 encounters for PU were identified. The majority of patients was 
female (51.0%), Caucasian (70.0%), and reported Medicare as their primary insurance 
(59.6%). Average age was 67.4 (SD= 19.5) and average number of physician visits was 
11.3 (SD= 14.9). Mean wound surface area was 8.8 cm2 (SD= 30.3). Overall average 
wound duration was 4.3 months (SD= 16.6). Of the 20,358 wounds, approximately 19.8 
% received CCO (n= 4,022). The majority of wounds treated with CCO were Stage III and 
IV (60.1% and 29.6%, respectively). Wounds treated with CCO had significantly more 
(p< 0.001) debridements of all methods (4.8, SD= 5.9) relative to the overall population 
(3.7, SD= 6.3). Problems treated with CCO were significantly more likely (p< 0.0001) 
to have an infection (65.3%) compared to the overall PU population (51.5%). Average 
number of visits where CCO was administered was 7.4 (SD= 5.9) and the average 
days of use with CCO was 53.3 days (SD= 58.0). Average number of CCO tubes used by 
patients was 2.2 (SD= 0.6). Mean days in service for CCO-treated wounds was 127.9 
(SD= 159.8), which was significantly higher compared to days in service for non-CCO 
treated wounds (98.9, SD= 157.7). CONCLUSIONS: Wounds treated with CCO had sub-
stantially longer days in service, more likely to receive debridement of all methods, 
and more likely to be infected relative to the overall PU population. Results from this 
analysis indicate that healthcare providers are using CCO in Stage III and IV PUs.
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OBJECTIVES: Linezolid is an important antimicrobial strategy to combat methicillin-
resistant Staphylococcus aureus (MRSA). However, it should be used with caution 
due to its high cost and to avoid the development of resistant strains. This study 
sought to determine the pattern of use of Linezolid in a large hospital in Fortaleza, 
Brazil. METHODS: This was a cross-sectional study carried out from 2013 to 2014, 
in which data were collected from the medical records of 170 patients admitted to 
medical wards and intensive care units of a general hospital and that were in use of 
Linezolid. The pharmacotherapeutic and microbiological parameters followed the 
Antimicrobial Stewardship Guideline (Infectious Diseases Society of America, 2012) by 
pharmacist and medical infectious disease team. For the calculation of the direct cost, 
the electronic source Brasíndice was used. RESULTS: The patients were in use of this 
antimicrobial had a mean age of 74.5 years and 56% were female. The most isolated 
bacteria were Staphylococcus aureus (13; 72%), Enterococcus (4; 22%), Streptococcus 
pneumoniae (1; 6%) and the most verified types of infection were pulmonary (137 
/ 64.32%), urinary (22 / 10.33%) and skin (9/4.22%). The average load time was 11.3 
days. The overall cost of the therapy with Linezolid was $216,075.41. CONCLUSIONS: 
Linezolid is strategic in the treatment against MRSA, especially in pneumonia, but 
should be used rationally to avoid adverse effects and increase of unnecessary costs. 
Thus, the determination of its pattern of use was a fundamental step to achieve better 
clinical outcomes in the multidisciplinary team setting.
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OBJECTIVES: Identify patient and clinical characteristics in the venous leg ulcer (VLU) 
population and examine patterns of enzymatic debridement utilization. METHODS: 
Retrospective, de-identified electronic medical records from 2007-2013 were extracted 
from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 hos-
pital-based outpatient wound centers. Patient, wound and encounter level charac-
teristics were examined. The treatment of interest was enzymatic debridement with 
clostridial collagenase ointment (CCO). RESULTS: A total of 9,091 patients, 25,734 
wounds, and 222,666 encounters for VLU were identified. The majority of patients was 
male (50.5%), Caucasian (74.1%), and reported Medicare as their primary insurance 
(53.4%). The average age was 68.9 (SD= 14.6) and the average number of physician 
visits was 17.7 (SD= 22.5). The mean wound surface area was 16.5cm2 (SD= 44.6). The 
overall average wound duration was 5.8 months (SD= 26.7). Of the 25,734 wounds, 
approximately 12.7% received CCO (n= 3,278). Wounds treated with CCO had sig-
nificantly more (p< 0.001) debridements of all methods (5.5, SD= 7.6) relative to the 
overall population (3.4, SD= 5.5). Problems treated with CCO were significantly more 
likely (p< 0.0001) to have an infection (74.2%) compared to the overall VLU population 
(60.5%). The average number of visits where CCO was administered was 2.1 (SD= 6.7) 
and the average days of use with CCO was 13.3 days (SD= 46.2). The average num-
ber of CCO tubes used by patients was 1.0 (SD= 1.1). Mean days in service for CCO-
treated wounds was 148.2 (SD= 196.5), which was significantly higher compared to 
days in service for non-CCO treated wounds (79.0, SD= 135.6). CONCLUSIONS: Wounds 
treated with CCO had substantially longer days in service, were more likely to receive 
debridement of all methods, and more likely to be infected relative to the overall VLU 
population. Results from this analysis indicate that health care providers are using 
CCO in more severe, difficult-to-heal VLUs.
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OBJECTIVES: Herpes zoster (HZ), also known as shingles, is a painful and com-
monly occurring condition in the U.S.. In spite of a universally recommended vac-
